alanine aminotransferase


Also found in: Dictionary, Thesaurus, Financial, Acronyms, Encyclopedia.
Related to alanine aminotransferase: aspartate aminotransferase

alanine aminotransferase

 [al´ah-nēn ah-me″no-trans´fer-ās]
ALT; alanine transaminase.

al·a·nine a·mi·no·trans·fer·ase (ALT),

(al'ă-nēn a-mē'nō-tranz'fer-ās),
An enzyme transferring amino groups from l-alanine to 2-ketoglutarate, or the reverse (from l-glutamate to pyruvate); one d-alanine transaminase effects the same reaction, but using d-alanine and d-glutamate. Serum concentration is increased in viral hepatitis and myocardial infarction.

alanine aminotransferase

Glutamine pyruvic transaminase, GPT Clinical chemistry An enzyme found primarily in the liver, with lesser amounts in the kidneys, heart and skeletal muscles; low levels of ALT are normal in the circulation; after liver damage, ALT is released into the bloodstream before more obvious clinical findings of liver damage–eg jaundice, occur; ↑ ALT is an early indicator of acute liver damage; ALT is measured as part of a panel of blood chemistry tests Ref ranges ♂ 10-32 U/L; ♀ 9-24 U/L; children 2 times > adults; AA is ↑ in viral hepatitis, drug-induced hepatitis, infectious mononucleosis, chronic hepatitis, intrahepatic cholestasis, cholecystitis, active cirrhosis, acute MI. See Aspartate amino transferase, Gamma-glutamyl transferase.

al·a·nine a·mi·no·trans·fer·ase

(ALT) (al'ă-nēn ă-mē'nō-trans'fĕr-ās)
An enzyme transferring amino groups from l-alanine to 2-ketoglutarate, or the reverse (from l-glutamate to pyruvate); serum concentration is increased in viral hepatitis and myocardial infarction.
Synonym(s): glutamic-pyruvic transaminase, serum glutamic-pyruvic transaminase.

al·a·nine a·mi·no·trans·fer·ase

(ALT) (al'ă-nēn ă-mē'nō-trans'fĕr-ās)
An enzyme transferring amino groups from l-alanine to 2-ketoglutarate, or the reverse (from l-glutamate to pyruvate); serum concentration is increased in viral hepatitis and myocardial infarction.
Synonym(s): glutamic-pyruvic transaminase, serum glutamic-pyruvic transaminase,
alanine transaminase.
References in periodicals archive ?
Mean [+ or -] SD (U/L) of Alanine Aminotransferase (ALT) in CKD Patients and Controls Subjects ALT (U/L) Predialysis CKD 14.73 Patients Hemodialysis CKD 7.62 Patients Normal Healthy 15.96 Controls Note: Table made from bar graph.
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
Onthe pyridoxal-5r-phosphate stimulation of aspartate aminotransferase and alanine aminotransferase in serum and erythrocytes of patients undergoing chronic haemodialysisand with kidneytransplants.
Sugar-sweetened beverage consumption was also positively associated with alanine aminotransferase levels (p for trend < 0.01).
Placebo was associated with a significant increase from baseline in body mass index, alanine aminotransferase and aspartate aminotransferase (0.17 kg/m(2), 3 and 2 U/l, respectively), whereas TGD was not.
The blood was allowed to clot and serum was separated for estimation of serum malondialdehyde (MDA) levels on spectrophotometer; and serum alanine aminotransferase (ALT) levels and aspartate aminotransferase (AST) levels on Merck Micorlab 200.
Objective: To investigate the relationship between hepatitis B virus (HBV) genotypes and hepatitis B early antigen (HBeAg) as well as the hepatitis C antibody, alanine aminotransferase (ALT) levels and liver inflammation and damage in chronic patients of hepatitis B.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were established using routine clinical chemistry testing.
No associations were seen between microvesicular steatosis and lobular inflammation or levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).
This double blind randomised placebo controlled study included 105 symptomatic patients with alanine aminotransferase (ALT) levels more than 2.5 times the upper limit of normal, jaundice and [greater than or equal to] three other symptomatic criteria of less than one month.
Liver function tests improved, with alanine aminotransferase decreasing from 35 to 24 IU/L, and aspartate aminotransferase from 27 to 23 IU/L.
Results of the 18,000-patient Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) showed that less than 1% of patients had elevations of the liver enzymes aspartate aminotransferase and alanine aminotransferase greater than three times the upper limit of normal, "which is similar to levels observed with available NSAIDs," Novartis noted, adding there were no cases of jaundice or hepatic failure with lumiracoxib 100-mg once-daily dosing in the clinical development program, it.